Condition: Idiopathic Pulmonary Fibrosis (IPF) · Sponsor: Shanghai Ark Biopharmaceutical Co., Ltd.
This is a phase 3 clinical study conducted in China. The primary objective is to compare the efficacy and safety of AK3280 400 mg versus placebo and active control (pirfenidone) in IPF patients.
This description comes directly from the study's public registry record.
Jayson Zhou · +8618796252099 · jayson.zhou@arkbiosciences.com
Always discuss trial participation with your own doctor first.
| China-Japan Friendship Hospital | Beijing, Beijing Municipality, China | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07719023